Brokers Issue Forecasts for JSPR Q1 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Jasper Therapeutics in a research report issued to clients and investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar expects that the company will earn ($1.48) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.78) EPS, Q4 2025 earnings at ($1.93) EPS, FY2025 earnings at ($6.83) EPS, FY2026 earnings at ($8.17) EPS, FY2027 earnings at ($9.50) EPS and FY2028 earnings at ($10.61) EPS.

A number of other equities research analysts have also recently issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. Royal Bank of Canada decreased their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. Finally, BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics currently has a consensus rating of “Buy” and an average target price of $67.75.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR opened at $5.87 on Monday. The stock has a market capitalization of $88.06 million, a P/E ratio of -1.24 and a beta of 2.18. The business has a 50-day moving average of $20.78 and a two-hundred day moving average of $20.04. Jasper Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $31.01.

Institutional Trading of Jasper Therapeutics

Several large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new position in shares of Jasper Therapeutics in the second quarter worth about $740,000. Rhumbline Advisers bought a new stake in Jasper Therapeutics during the 2nd quarter worth about $300,000. American Century Companies Inc. lifted its position in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after purchasing an additional 3,032 shares during the period. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics during the 3rd quarter worth approximately $59,000. Finally, Fernwood Investment Management LLC raised its stake in shares of Jasper Therapeutics by 6.9% during the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after buying an additional 3,427 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.